Quality-adjusted survival following treatment of malignant pleural effusions with indwelling pleural catheters

Chest

Volumn 145, Issue 6, 2014, Pages 1347-1356

  Ost, David E ^a   Jimenez, Carlos A ^a   Lei, Xiudong ^a   Cantor, Scott B ^a   Grosu, Horiana B ^a   Lazarus, Donald R ^b   Faiz, Saadia A ^a   Bashoura, Lara ^a   Shannon, Vickie R ^a   Balachandran, Dave ^a   Noor, Lailla ^a   Hashmi, Yousra B ^a   Casal, Roberto F ^b,c   Morice, Rodolfo C ^a   Eapen, George A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CATHETER OCCLUSION; CATHETER REMOVAL; CLINICAL TRIAL; COHORT ANALYSIS; DEATH; DYSPNEA; EMPYEMA; FEMALE; HUMAN; HYDROTHORAX; INDWELLING CATHETER; MALE; MALIGNANT PLEURA EFFUSION; OBSERVATIONAL STUDY; PLEURAL CATHETER; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RISK FACTOR; THORAX DRAINAGE; THORAX PAIN; WOUND INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; CATHETERS, INDWELLING; COHORT STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PLEURAL CAVITY; PLEURAL EFFUSION, MALIGNANT; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84901819892     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-1908     Document Type: Article

References (18)

1. Haas AR, Sterman DH, Musani AI. Malignant pleural effusions: management options with consideration of coding, billing, and a decision approach. Chest. 2007;132(3):1036-1041.
2. Simoff MJ, Lally B, Slade MG, et al. Symptom management in patients with lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5-suppl):e455S-497S.
3. Davies HE, Mishra EK, Kahan BC, et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA. 2012;307(22):2383-2389.
4. Putnam JB Jr, Light RW, Rodriguez RM, et al. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer. 1999;86(10):1992-1999.
5. Van Meter ME, McKee KY, Kohlwes RJ. Efficacy and safety of tunneled pleural catheters in adults with malignant pleural effusions: a systematic review. J Gen Intern Med. 2011;26(1):70-76.
6. van den Toorn LM, Schaap E, Surmont VF, Pouw EM, van der Rijt KC, van Klaveren RJ. Management of recurrent malignant pleural effusions with a chronic indwelling pleural catheter. Lung Cancer. 2005;50(1):123-127. (Pubitemid 41297479)
7. Ohm C, Park D, Vogen M, et al. Use of an indwelling pleural catheter compared with thorascopic talc pleurodesis in the management of malignant pleural effusions. Am Surg. 2003;69(3):198-202.
8. Maskell NA. Treatment options for malignant pleural effusions: patient preference does matter. JAMA. 2012;307(22):2432-2433.
9. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271-292. (Pubitemid 34143147)
10. Gray B. The CMPRSK Package. The Comprehensive R Archive Network. Vienna, Austria: Vienna University of Economics and Business Administration; 2007.
11. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ. 2004;329(7459):224-227. (Pubitemid 39013284)
12. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276(15):1253-1258. (Pubitemid 26337709)
13. Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Gold MR. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on Cost Effectiveness in Health and Medicine. Pharmacoeconomics. 1997;11(2):159-168. (Pubitemid 27086806)
14. Atkins D, DiGuiseppi CG. Broadening the evidence base for evidence-based guidelines. A research agenda based on the work of the US Preventive Services Task Force. Am J Prev Med. 1998;14(4):335-344.
15. Räsänen P, Roine E, Sintonen H, Semberg-Konttinen V, Ryynänen OP, Roine R. Use of quality-adjusted life years for the estimation of effectiveness of health care: a systematic literature review. Int J Technol Assess Health Care. 2006;22(2):235-241.
16. Ferguson ND, Scales DC, Pinto R, et al Canadian Critical Care Trials Group. Integrating mortality and morbidity outcomes: using quality-adjusted life years in critical care trials. Am J Respir Crit Care Med. 2013;187(3):256-261.
17. Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. 2008;6:84.
18. Casal RF, Bashoura L, Ost D, et al. Detecting medical device complications: lessons from an indwelling pleural catheter clinic. Am J Med Qual. 2013;28(1):69-75.